Inve India ▾

Thyrocare Technologies share price & results

Thyrocare Technologies Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Pan-India B2B diagnostics chain that runs sample-testing labs for franchisees, hospitals and health platforms.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue240 ₹ crore+24.4% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin32.0 %+2.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit51.0 ₹ crore+34.2% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity31.80 %+12.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin23.83 %+2.6 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)21.30 %+0.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

7 of 11 judged targets kept · 18 open · verdicts reflect calls analysed to Q1 FY27.

Thyrocare Technologies Limited management guidance track record on Inve: 29 targets tracked across analysed earnings calls (7 achieved, 4 missed, 18 open).

TargetOriginal wordingSaidLatest callVerdict
Complaints per MillionBelow 3.4 complaints per million
Call transcript, Q2 FY26 · 14 Oct 2025		Q2 FY26Q1 FY27:Maintained Six Sigma levels at 3.1 complaints per million tests, continuing to meet the target.
Call transcript, Q1 FY27 · 23 Jul 2026		Achieved
Acquisition IntegrationStabilization within 3 to 6 months
Call transcript, Q3 FY25 · 23 Jan 2025		Q3 FY25Q1 FY27:This is a closed promise from a prior fiscal year; no new updates provided.
Call transcript, Q1 FY27 · 23 Jul 2026		Achieved
Long-term Partnerships Business Growth1.5x franchise business growth
Call transcript, Q3 FY26 · 28 Jan 2026		Q3 FY26Q1 FY27:Q1 partnership growth (26%) was lower than franchise growth (27%), missing the 1.5x target for the quarter and putting the long-term promise at risk.
Call transcript, Q1 FY27 · 23 Jul 2026		At Risk

Source: Inve Guidance Tracker for Thyrocare Technologies Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Thyrocare Technologies Limited's 29 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 26 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹470.65 +1.62% · +₹7.5

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −62.8% 1Y

₹0.5k₹1.0k₹1.5kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 28 Jan 2026Q4 FY26 — 12 May 2026Q1 FY27 — 23 Jul 2026

1Y: ₹1,266.1 on 24 Oct 2025 → ₹470.65. High ₹1,591.9 (18 Nov 2025), low ₹349.55 (30 Mar 2026).

Previous close
₹463.15
Market cap
₹7.5k Cr
52-week range
₹349.55 – ₹1,591.9
One year
−63.51%
Price to earnings (TTM to Jun 2026)
41.62×
Return on equity (TTM to Jun 2026)
31.80%

Overview

Symbol
NSE:THYROCARE
Exchange
NSE
Currency
INR

What Thyrocare Technologies Limited does

Based on the company's own presentations, annual report and earnings calls.

Thyrocare is a B2B pathology diagnostics company built on a hub-and-spoke model: samples are collected by franchisee collection centres, company-owned phlebotomists and partner organisations, then routed to a network of centralised, NABL-accredited processing laboratories across India (plus one lab in Tanzania) for testing. It earns revenue by charging its franchisees, hospitals, online diagnostic aggregators, healthcare platforms, employee-wellness programmes and insurance/corporate partners for tests processed through its labs, rather than running its own retail collection outlets. Alongside its core pathology (blood/sample) testing business it also operates a radiology imaging business through its Pulse Hi-Tech radiology centres, and is expanding into specialty segments such as genomics (including NIPT), oncology markers, autoimmune and allergy diagnostics.

Segments

  • Pathology
  • Radiology
Total laboratories
41 (40 in India + 1 in Tanzania)
Lab network composition
2 Central Processing Labs, 21 Regional Processing Labs, 6 Satellite Processing Labs, 5 Hybrid Labs, 4 Acquired Labs, 2 Zonal Processing Labs
Quarterly active franchisees
~10,800 (record high, Q4FY26)
Pin codes served
5,400+ pin codes across India
Test menu offered
1,275+ tests
Company-owned phlebotomy fleet
2,000+ phlebotomists
Founded 1996Headquarters Navi Mumbai, Maharashtra, India (Turbhe)Employees 2,092 (FY26 (year ended March 2) Company website

How the price took the results

close before → close after

Q1 FY27
−2.3%
23 Jul
Q4 FY26
−1.8%
12 May
Q3 FY26
+1.1%
28 Jan

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Thyrocare Technologies Limited

Free account: one company. Everything above stays public.

Write why you follow Thyrocare Technologies Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Thyrocare Technologies Limited

Guides on how to read this kind of business and the numbers that matter.